Question 1

What are the benefits of IGF-1 peptide?

Accepted Answer

Begin with the outcomes that carry numbers, because the word benefit covers a very wide range of things in this literature. Three families of outcome have been measured. The first is growth in children who cannot produce enough of the hormone themselves. The second is blood sugar handling in people whose bodies resist insulin, and the third is a set of brain and behaviour measurements in rare inherited disorders. A 2009 review also lists other applications that have either been considered or are undergoing clinical trial, and that list is long. Read it as a map of where researchers have looked rather than as a catalogue of established results. The same review closes by stating that it is unlikely that mecasermin will be useful beyond the orphan indications of severe insulin resistance and GH insensitivity. Mecasermin is the approved recombinant form of the hormone, and an orphan indication is a condition rare enough to carry its own regulatory category.

Question 2

What does an IGF-1 blood test measure?

Accepted Answer

A test for IGF-1 reports how much of the hormone was circulating at the moment the sample was drawn, which makes it a reading of what the body produces rather than of anything taken. That production is driven from upstream. A 2009 review describes how growth hormone exercises its growth effects by stimulating insulin-like growth factor I (IGF-I) synthesis in the liver, so the figure on a laboratory report is partly an indirect measurement of pituitary activity. One further complication belongs inside the sentence rather than in a footnote: hardly any of the hormone travels alone, because most of it circulates bound to a carrier known as binding protein 3. A routine assay counts the bound and the unbound portions together, so a single number cannot establish how much is reaching any particular tissue.

Question 3

Why would a clinician order a test for IGF-1?

Accepted Answer

Two reasons dominate the clinical literature, and both of them are really questions about growth hormone rather than about IGF-1 itself. The first is diagnosis: a 2015 review states that measurement of IGF-I is of the utmost importance in the diagnosis and treatment of, for example acromegaly and growth hormone deficiency, two conditions sitting at either end of one axis. Acromegaly is an excess of growth hormone in an adult, usually produced by a benign pituitary tumour, and a 1994 review in Drugs calls a raised plasma reading the single best test to make the diagnosis. The second reason is follow-up, because once a tumour has been dealt with, hormone output is best assessed by determining whether plasma IGF-I returns to the normal range. So the assay is ordered to settle a question about a gland, and it was never constructed to indicate whether anybody would gain from an injection.

Question 4

What is the reference range for an IGF-1 test?

Accepted Answer

No single pair of numbers answers this, and the reason lies in how the assay works rather than in any gap in the literature. A reference range for IGF-1 is produced by the laboratory running the test and indexed to age, because circulating concentrations change across a lifetime, so a result arrives as a position inside an age band rather than as a figure anybody can carry between reports. The one threshold carrying regulatory weight is written the same way: severe primary IGF-1 deficiency is defined as basal IGF-1 standard deviation score (SDS) less than or equal to -3 and height SDS less than or equal to -3. Three standard deviations below the mean is roughly the lowest reading in a thousand, and a Canadian funding review describes the consequence plainly, recording that approximately 5 cases of SPIGFD are diagnosed each year in that country. That is how narrow the band becomes at the end where an approval actually exists.

Question 5

What does a low IGF-1 result point to?

Accepted Answer

A low reading says the body is not making much of the hormone, and the clinical work then asks why. The route that produced an approved medicine runs through children who cannot answer growth hormone at all. A 2023 study notes that the role of IGF-1 was discovered through studies involving deficient patients with short stature, including Laron syndrome individuals. Laron syndrome is a rare inherited insensitivity to growth hormone. The licensed medicine follows that logic. It was launched for growth failure in children with primary IGF deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Those antibodies mean the immune system has learned to disable injected growth hormone, so replacing the hormone further down the chain is the only route left. A low reading in an adult who is in neither group sits outside all of that. A 2015 review is blunt about the limit: its bioactivity is incompletely understood.

Question 6

Does a test result tell you what taking IGF-1 would do?

Accepted Answer

Not in any way the measured record supports, and this is the most useful distinction on the page. Every outcome with a number attached was recorded in somebody whose own production was very low, or whose receptor could not answer growth hormone at all. The definition quoted above sets that bar three standard deviations below the age-matched mean. A reading inside the ordinary range therefore puts a person outside every group in which an outcome was ever recorded. The gap underneath that one is about evidence rather than biology. A 2026 review sorts this whole category into evidence tiers from regulatory-grade randomized trial data to a complete absence of human studies. The same review names IGF-1 Long R3 (IGF-1 LR3) among the IGF-1 analogues it covers, which is the version sold online. So a laboratory number and an injection answer different questions, and only the first has a settled clinical use behind it.

Question 7

What did IGF-1 do for insulin resistance?

Accepted Answer

This outcome gets the least publicity and some of the most consistent reporting. A 2009 review records that rhIGF-I has also been effective as an insulin-sensitizing agent in severe insulin-resistant conditions. Those are conditions in which a person's own insulin has largely stopped working. The group studied is extreme rather than ordinary. A 2018 case report of Donohue syndrome, the most severe inherited form of insulin resistance, records that mecasermin has been reported to improve metabolic control and increase lifespan in DS patients. DS there stands for Donohue syndrome. The same report puts the entire published experience at more than 30 treated patients worldwide. The wider diabetes question then stalled outright. The same 2009 review states that there are no ongoing clinical trials because of concern about risk of retinopathy and other complications. Retinopathy is damage to the small blood vessels of the retina. An effect found and not pursued is a different thing from an effect looked for and never found.

Question 8

Which outcomes did the Rett syndrome work record?

Accepted Answer

Rett syndrome carries the fullest set of measured outcomes outside growth, and taking them one at a time tells a reader much more than the headline does. A 2025 systematic review reports that IGF-1 may help preserve social engagement and cognitive function in RTT, the abbreviation for Rett syndrome. The same review reports that autonomic control and behavioral outcomes have been inconsistent. Autonomic control covers the automatic jobs, such as heart rate. It also records that brain-wave readings varied widely between children. Of four outcome families, then, one reads positive, two read inconsistent and the last reads unresolved. The breathing result is the most specific item in the record, and it came from sorting the children afterwards. Those with moderate-severe apnoea and breathing improvement (Responder group) were analysed separately from the rest. A group picked once the results are in is a guess about who might gain, rather than proof that anybody did.

Question 9

Which other inherited conditions has it been measured in?

Accepted Answer

Three more appear, and all of them sit at the early end of the evidence. A 2016 review reports that clinical pilot studies and early reports have supported the preliminary efficacy of IGF-1 and related compounds in Rett Syndrome. The same review adds that evidence is mounting for its use in Phelan McDermid Syndrome and Fragile X Syndrome. Both are single-gene disorders of brain development, and both were approached because the same signalling system is disturbed in them. It also records that in ASD, clinical trials are ongoing, ASD being autism spectrum disorder. Evidence mounting and trials ongoing describe activity rather than findings, and anybody weighing what to believe needs to read them that way. What these conditions share with growth failure is the shape of the group rather than anything about muscle: an inherited, diagnosed fault in one signalling system, managed in a specialist clinic.

Question 10

What has IGF-1 LR3 itself been measured doing?

Accepted Answer

Almost all of it was done in fetal sheep, which is a stranger answer than the question expects. In a 2020 experiment, near-term fetal sheep were studied across a week of late gestation, receiving either IGF-1 LR3 or vehicle, and what the investigators measured was the blood supply to the heart, which kept pace as the heart enlarged. An earlier experiment in the same animal asked what kind of growth this was, concluding that IGF-1 stimulates cardiomyocyte division in vivo, and that hyperplastic growth is the most likely explanation. Hyperplastic means more cells rather than larger ones, and that distinction carries the entire result. The only remaining measurement is a laboratory one, in which LR3 IGF-1 showed bioactivity of cell proliferation compared to the standard IGF-1, recorded while testing a yeast production method rather than any therapy. Cardiac tissue in an unborn sheep and skeletal muscle in a training adult are not the same subject, and the second one has not been measured.

Question 11

Does IGF-1 help with fat loss?

Accepted Answer

No trial among the research behind this page has set body fat as an outcome in anybody given IGF-1, and the single place fat appears in this record points in the opposite direction. A 2009 review lists among the common adverse effects accumulation of body fat, and coarsening of facies, where facies describes the appearance of the face. So fat gain belongs to the documented list and fat loss appears on no list at all. A 2026 review adds appetite changes, and dysglycaemia for the unregulated analogues, dysglycaemia meaning blood sugar wandering outside its usual range. Those are mechanisms capable of pushing weight in either direction, and nobody among the research behind this page has measured which direction it actually takes. The honest position is that the question has not been asked, rather than that it was asked and answered with a no.

Question 12

How long did it take before anything was measured?

Accepted Answer

Every measured timescale in this record is long, and not one of them belongs to the question most readers are actually asking. The shortest is a 20-weeks phase I open label trial of mecasermin in children with RTT, in which breathing was the measurement that moved, while the growth outcomes run very much longer. In a small noncomparative trial in children with GH insensitivity syndrome, the mean increase in the height standard deviation score was +1.4 after 6.5-7.5 years of mecasermin therapy, and a separate group of children with IGF-1 deficiency syndrome were monitored for 4-5 years of rhIGF-1 treatment. Twenty weeks is therefore the floor and seven years the ceiling, and both figures were recorded in children carrying a diagnosis. Nothing among the research behind this page records how quickly IGF-1 LR3 does anything in an adult, because no experiment covered here ever gave it to one.

Question 13

What has been measured for IGF-1 in bodybuilding?

Accepted Answer

Nothing has been recorded as an outcome, and a 2026 review written for clinicians is explicit about why. It states the regulatory position first, naming the absence of regulatory approval for physique- or performance-related indications. It then names a second problem: uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains. On the evidence itself, the review points to uncertainty around putative performance and recomposition benefits. Recomposition is the gym term for losing fat and gaining muscle at once. Two separate problems are being flagged there, and they are worth keeping apart. One is that no outcome has been recorded in anybody. The other is that the contents of an unregulated vial are unknown, so even a careful experiment would not know what it had given. The same review reports adverse effects across this class: fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions. What the record does not hold anywhere is a measured gain in muscle.

Question 14

Does the growth signal behind the benefit carry a cancer concern?

Accepted Answer

It is one mechanism running in both directions, which is exactly why the concern belongs on a page about benefits. Every outcome above depends on IGF-1 instructing cells to divide and instructing them not to die on schedule. A 2009 review puts the other face of that plainly, stating that the anti-apoptotic properties of IGF-I are implicated in cancer pathogenesis. Anti-apoptotic means cells become less willing to die at the moment they ordinarily would, and the same review calls that a concern for long-term therapy. A 2026 review names the same worry for the analogues sold outside a pharmacy, calling the mitogenic concerns biologically plausible but unproven. Mitogenic means prompting cells to divide. The word unproven needs reading in both directions at once. It means that no incidence figure exists among the research behind this page, and equally that the concern has not been retired by anybody. Neither a measured risk nor a dismissed one describes it accurately. The IGF-1 safety page carries the adverse-event record in full.

Question 15

Does the binding-protein version produce a different outcome?

Accepted Answer

Two preparations exist, and the second was built to repair a problem with the first. Mecasermin rinfabate pairs the hormone with its carrier protein. A 2007 review states that it prolongs the half-life of rhIGF and should counteract acute adverse events, particularly hypoglycemia. On what it achieves, though, very little moved. A 2008 review reports that its effects have been explored in diabetes, severe insulin resistance, osteopaenia, burns and growth hormone insensitivity syndrome, with outcomes similar to those of rhIGF-I alone. A 2006 review is blunter still, noting that there are no published data on the efficacy of mecasermin rinfabate in treating growth disorders. So a carrier protein changed how long the hormone lasted, while the outcomes attached to it still read much like those of the unbound version. Changing how a molecule is delivered is not the same as changing what it does once it arrives.

IGF-1: what the research measured